Treatment Outcome of Ankylosing Spondylitis in Srinagarind Hospital
Sithayarat Uthaiphan1, Chingching Foocharoen2, Siraphop Suwannaroj2, Patnarin Pongkulkiat2, Ajanee Mahakkanukrauh2
Affiliation : 1Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, 2Division of Rheumatology Medicine, Department of Internal Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand
Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), Visual analog scale (VAS), ESR (erythrocyte sedimentation rate), and CRP (C-reactive protein) are the tools for assessing disease activity.
Objective: The purpose of the present study was to determine the treatment outcome of AS patients in the Rheumatology clinic at Srinagarind Hospital.
Materials and Methods: AS patients who were follow-up between 1 January 2015 and 31 December 2019. The primary outcome was the disease activities by BASDAI, and ASDAS at the initial treatment and the last visit. Moreover, the factors consisting of age, duration of disease, and duration of DMARDs (Disease-Modifying Antirheumatic drugs) used were evaluated for the correlation of persistent high disease activity (BASDAI ≥4 or ASDAS ≥2.1) in patients after treatment.
Results: A total of 42 AS patients consist of 31 males (73.80%). The average age was 41 years old, and the average duration of disease and the duration of DMARDs used were 9.32 and 9.02 years, respectively. Biologic DMARDs used were 6 (14.28%). At the first visit, there were high disease activities patients with BASDAI ≥4; 9 (21.43%), ASDAS ≥2.1; 34 (80.95%) and low disease activities patients with BASDAI <4; 32 (76.19%), ASDAS <2.1; 6 (14.29%). At the last visit, there were high disease activities patients with BASDAI ≥4; 4 (9.52%), ASDAS ≥2.1; 21 (50.00%) and low disease activities patients with BASDAI <4; 37 (88.10%), ASDAS <2.1; 18 (42.86%). The high disease activities patients decreased by 55% after treatment by BASDAI score and decreased by 38% by ASDAS score. Low disease activities group of patients were associated with the use of biologic DMARDs. The correlation of high disease activity to age, duration of disease, and duration of DMARDs used were not significant p-values=0.79, 0.92 and 0.92, respectively.
Conclusion: Most of AS patient can achieved BASDAI goal after treatment.
DOI:10.35755/jmedassocthai.2023.S01.13801
Keywords : Ankylosing spondylitis; BASDAI; ASDAS; VAS; ESR; CRP; DMARDs
All Articles
Download